Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.50 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712365 | 0.83 | MEN1 (0.56) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL6573133 | 0.83 | MEN1 (0.56) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3676901 | 0.82 | MEN1 (0.41) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17629809 | 0.81 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1208087 | 0.81 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL4256715 | 0.81 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Nitric Acid SCHEMBL5712388 | 0.80 | MEN1 (0.53) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL28397518 | 0.78 | MEN1 (0.84) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL28171779 | 0.77 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL7031982 | 0.77 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240819-B1 | Amino acid compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2025-03-04 | — | — | US | claimed |
| WO-2016099465-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC (US) | 2016-06-23 | — | — | WO | claimed |
| WO-2015095236-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | KRAMER RONALD (US) | 2015-06-25 | — | — | WO | claimed |
| US-12441615-B2 | Method of administering nitric oxide gas | THERMOLIFE INTERNATIONAL, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250170173-A1 | METHODS OF INCREASING BLOOD OXYGEN SATURATION | THERMOLIFE INT LLC (US) | 2025-05-29 | — | — | US | disclosed |
| US-12156886-B2 | Methods of increasing blood oxygen saturation | THERMOLIFE INTERNATIONAL, LLC (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4433066-A1 | METHODS OF INCREASING BLOOD OXYGEN SATURATION | Thermolife International, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240122967-A1 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | THERMOLIFE INTERNATIONAL, LLC | 2024-04-18 | — | — | US | disclosed |
| US-20240122969-A1 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | THERMOLIFE INTERNATIONAL, LLC | 2024-04-18 | — | — | US | disclosed |
| US-20240122966-A1 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | THERMOLIFE INTERNATIONAL, LLC | 2024-04-18 | — | — | US | disclosed |
| US-20240122968-A1 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | THERMOLIFE INTERNATIONAL, LLC | 2024-04-18 | — | — | US | disclosed |
| US-8048921-B2 | Amino acid compounds | THERMOLIFE INTERNATIONAL, LLC | 2011-11-01 | — | — | US | disclosed |
| US-7714166-B2 | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090143616-A1 | Process for Producing Carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090137670-A1 | Amino Acid Compounds | THERMOLIFE INTERNATIONAL, LLC | 2009-05-28 | — | — | US | disclosed |
| CN-101304965-A | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL CO (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1930314-A1 | PROCESS FOR PRODUCING CARNITINAMIDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| JP-2006306847-A | COPPER COMPOUND-INCORPORATED COMPOSITION | TAISHO PHARMACEUT CO LTD | 2006-11-09 | — | — | JP | disclosed |
| EP-1224161-A1 | NITROXY DERIVATIVES OF (R) AND (S)-CARNITINE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001010819-A1 | NITROXY DERIVATIVES OF (R) AND (S)-CARNITINE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137670-A1 | Amino Acid Compounds | OAT, CRAT, SLC25A20 | MEN1 2290/4885KMT2A 2525/4885CYP1A2 1272/4885 |
| US-20090143616-A1 | Process for Producing Carnitinamide | CRAT, NISCH, NAAA | MEN1 343/4885KMT2A 754/4885CYP1A2 2648/4885 |
| US-12240819-B1 | Amino acid compositions | SLC10A2, SLC1A5, CPT1B | MEN1 2586/4885KMT2A 3774/4885CYP1A2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.